Does Olmesartan Medoxomil increase the levels of serum urea and creatinine? Does the proteinuria increase when patients taking Olmesartan happen to reduce the dose?
Giving ACE inhibitors or ARBs in patients with chronic kidney disease has long-term benefits as long as the potassium level is up to 5.0 mmol/l and the initial rise in urea and creatinine does not go beyond 20-30% of baseline.
Olmesartan being an ARB will follow the same course and benefits as other ARBs like Losartan, Valsartan, and Candesartan.
One has to be more careful about Potassium and kidney function in patients with stage 4 or 5 CKD (see reference below).
Article ACE inhibitors and ARBs: Managing potassium and renal function
Patients with chronic renal illness on high-dose Angiotensin Receptor Blockers (ARB) therapy do not experience any clinically meaningful long-term adverse effects on serum potassium or creatinine levels. As a result, it is a crucial treatment strategy for achieving additional decreases in urine protein is extremely vital in alleviating the signs and symptoms associated with chronic renal failure.